Carly Holdings Limited (CL8NE) News

Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day

Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including...

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced...

Form 8-K - Current report

Form 424B7 - Prospectus [Rule 424(b)(7)]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments

Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments PR Newswire NEW HAVEN...

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase...

Biohaven Announces Proposed Public Offering of Common Shares

Biohaven Announces Proposed Public Offering of Common Shares PR Newswire NEW HAVEN, Conn., April 17, 2024 NEW...

Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates

Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of...

Form 8-K - Current report

Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments

Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments PR...

Form 8-K - Current report

Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncolo

Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd...

Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire NEW HAVEN, Conn., Jan. 2...